72.83
전일 마감가:
$70.87
열려 있는:
$71.08
하루 거래량:
8.03M
Relative Volume:
1.46
시가총액:
$112.93B
수익:
$54.98B
순이익/손실:
$7.77B
주가수익비율:
29.25
EPS:
2.49
순현금흐름:
$9.14B
1주 성능:
+3.44%
1개월 성능:
+1.56%
6개월 성능:
+7.70%
1년 성능:
-5.13%
아스트라제네카 ADR Stock (AZN) Company Profile
명칭
Astrazeneca PLC
전화
44 20 3749 5000
주소
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
AZN을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
AZN
Astrazeneca PLC
|
72.83 | 218.30B | 54.98B | 7.77B | 9.14B | 2.49 |
아스트라제네카 ADR Stock (AZN) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-04-15 | 개시 | Exane BNP Paribas | Outperform |
2025-02-13 | 업그레이드 | UBS | Neutral → Buy |
2025-02-12 | 개시 | Morgan Stanley | Overweight |
2024-11-20 | 업그레이드 | UBS | Sell → Neutral |
2024-11-06 | 업그레이드 | Deutsche Bank | Sell → Hold |
2024-09-13 | 다운그레이드 | Deutsche Bank | Hold → Sell |
2024-05-30 | 개시 | Goldman | Buy |
2024-04-16 | 업그레이드 | Deutsche Bank | Sell → Hold |
2024-02-08 | 다운그레이드 | Deutsche Bank | Hold → Sell |
2024-01-23 | 개시 | Morgan Stanley | Overweight |
2024-01-16 | 재개 | UBS | Sell |
2024-01-03 | 다운그레이드 | Jefferies | Buy → Hold |
2023-12-18 | 개시 | HSBC Securities | Buy |
2023-09-25 | 업그레이드 | Jefferies | Hold → Buy |
2023-07-14 | 개시 | HSBC Securities | Buy |
2023-07-12 | 업그레이드 | UBS | Neutral → Buy |
2023-07-05 | 다운그레이드 | Deutsche Bank | Buy → Hold |
2023-04-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2023-01-05 | 개시 | BMO Capital Markets | Outperform |
2022-09-15 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
2022-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2022-08-29 | 업그레이드 | Argus | Hold → Buy |
2022-06-14 | 다운그레이드 | UBS | Buy → Neutral |
2022-02-11 | 업그레이드 | DZ Bank | Sell → Hold |
2021-12-07 | 다운그레이드 | Jefferies | Buy → Hold |
2021-08-12 | 재개 | JP Morgan | Overweight |
2021-04-12 | 다운그레이드 | Argus | Buy → Hold |
2021-03-16 | 업그레이드 | Jefferies | Hold → Buy |
2021-02-25 | 업그레이드 | UBS | Neutral → Buy |
2021-01-15 | 개시 | Deutsche Bank | Buy |
2020-12-07 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2020-11-30 | 업그레이드 | UBS | Sell → Neutral |
2020-11-11 | 업그레이드 | HSBC Securities | Reduce → Hold |
2020-09-29 | 개시 | Berenberg | Buy |
2019-11-22 | 개시 | SVB Leerink | Outperform |
2019-10-25 | 업그레이드 | Liberum | Hold → Buy |
2019-04-02 | 다운그레이드 | UBS | Neutral → Sell |
2019-02-05 | 개시 | Exane BNP Paribas | Outperform |
2019-01-25 | 업그레이드 | Shore Capital | Hold → Buy |
2018-12-11 | 재개 | Jefferies | Hold |
2018-10-09 | 개시 | Guggenheim | Buy |
2018-08-16 | 다운그레이드 | Jefferies | Buy → Hold |
2018-03-19 | 업그레이드 | Jefferies | Hold → Buy |
2018-02-06 | 재확인 | Leerink Partners | Mkt Perform |
2018-02-05 | 재확인 | Bernstein | Outperform |
2018-01-18 | 재확인 | Leerink Partners | Mkt Perform |
2017-12-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
2017-10-16 | 업그레이드 | Credit Suisse | Neutral → Outperform |
2017-09-25 | 업그레이드 | Exane BNP Paribas | Neutral → Outperform |
2017-09-22 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
모두보기
아스트라제네카 ADR 주식(AZN)의 최신 뉴스
AstraZeneca: promising results for Imfinzi in gastric cancer - marketscreener.com
AstraZeneca: camizestrant effective in breast cancer - marketscreener.com
AstraZeneca Pharma India Share Price Jumps Post Q4 Profit, Margin Growth - NDTV Profit
PRESS DIGEST- Financial TimesJune 2 - marketscreener.com
AstraZeneca's (AZN) DATROWAY Shows Promise in Lung Cancer Trials | AZN Stock News - GuruFocus
AstraZeneca (AZN) Reports Positive Phase III Trial Results for IMFINZI | AZN Stock News - GuruFocus
AstraZeneca (AZN) Reports Promising Phase III Trial Results for Camizestrant | AZN Stock News - GuruFocus
AstraZeneca (AZN): ENHERTU Demonstrates Significant Survival Boost in Gastric Cancer Trial | AZN Stock News - GuruFocus
AstraZeneca breast cancer medicine slows disease by over six months - The Economic Times
Blood test-guided treatment with AstraZeneca pill cuts breast cancer progression risk - marketscreener.com
A funding flashpoint, Pfizer’s $1B poster and AstraZeneca advertising - BioPharma Dive
AstraZeneca drug could help keep a common breast cancer at bay - BioPharma Dive
IMFINZI (Durvalumab) Regimen Reduced Risk Of Progression, Recurrence Or Death By 29% In Early-Stage Gastric Cancer Versus Chemotherapy Alone In Matterhorn Phase III Trial - marketscreener.com
Blood test-guided treatment with AstraZeneca pill cut risk of breast cancer progression, study finds - marketscreener.com
AstraZeneca Breast Cancer Pill Slows Disease by Over Six Months - Bloomberg.com
AstraZeneca Reaches $51 Million Settlement in Pay-for-Delay Suit - Bloomberg Law News
AstraZeneca agrees to $51 million settlement in Seroquel antitrust class action - Reuters
Danaher Partners With AstraZeneca to Support Precision Medicine - TradingView
AstraZeneca - Britannica
AstraZeneca, Danaher to Develop New Precision Medicine Diagnostic Tools - marketscreener.com
Barclays Remains Upbeat on AstraZeneca, Expects US Conference to Highlight Breast Cancer Franchise - marketscreener.com
AstraZeneca gets CDSCO nod for new indications of Benralizumab, Osimertinib in India - Medical Dialogues
Danaher Corporation (DHR) Launches Partnership with AstraZeneca PLC (AZN) to Scale Next-Gen Precision Medicine Tests - Yahoo Finance
AstraZeneca Inks $51.4M Settlement In Pay-For-Delay Case - Law360
Danaher in partnership with AstraZeneca for diagnostic tests for precision medicine (DHR:NYSE) - Seeking Alpha
Danaher partners with AstraZeneca on AI diagnostics By Investing.com - Investing.com Nigeria
Bispecific Antibody Drug Conjugates Clinical Trials Bispecific ADC Market Size Insight - GlobeNewswire Inc.
RNA Targeting Small Molecule Drug Discovery Research Report 2025 - GlobeNewswire Inc.
Targeted Drug Delivery Research Business Analysis Report 2024-2030 with Focus on 30+ Key Players Such as AbbVie, Amgen, AstraZeneca, Becton Dickinson and Co, & Bristol-Myers Squibb - Yahoo Finance
Eli Lilly vs. AstraZeneca: Which Pharma Powerhouse is the Better Buy? - Yahoo Finance
Transcript : AstraZeneca PLCSpecial Call - marketscreener.com
AstraZeneca and Global Transparency - AstraZeneca
Ethics and Compliance - AstraZeneca
Nature - AstraZeneca
Inclusion and diversity - AstraZeneca
Community investment - AstraZeneca
AstraZeneca (AZN) Collaborates on Major AI Infrastructure in Swe - GuruFocus
AstraZeneca PLC (AZN) Trial: Airsupra Cuts Severe Asthma Risk by 47% - MSN
AstraZeneca (AZN) Executive Joins Rapid Micro Biosystems' Board | AZN Stock News - GuruFocus
AstraZeneca (AZN) Gains EU Panel Support for Imfinzi in Bladder Cancer - GuruFocus
AstraZeneca (AZN) Nears EU Approval for Imfinzi in Bladder Cance - GuruFocus
AstraZeneca wins EU backing for Imfinzi in bladder cancer - Seeking Alpha
AstraZeneca Gains Positive Opinion for Imfinzi's Bladder Cancer Indication in EU - marketscreener.com
AstraZeneca: CHMP gives positive opinion for Imfinzi - marketscreener.com
EU recommends AstraZeneca bladder cancer treatment for approval - Sharecast.com
AstraZeneca Plc Imfinzi recommended for EU approval in bladder cancer - DirectorsTalk Interviews
AstraZeneca's Imfinzi Wins EU Approval Recommendation for Bladder Cancer - marketscreener.com
AstraZeneca Says Imfinzi Recommended In EU For Bladder Cancer - marketscreener.com
ASCO Preview: Major Solid Tumor Readouts Include AstraZeneca/Daiichi, Gilead ADCs - insights.citeline.com
AstraZeneca (AZN) Partners in Sweden's Largest AI Supercomputer Initiative | AZN Stock News - GuruFocus
Gouty Arthritis Market Overall Study Report 2025-2032 | - openPR.com
아스트라제네카 ADR (AZN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):